{"organizations": [], "uuid": "fbd6a93f08379bc945fff61f8635c7458bc3a265", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-glaxosmithkline-new-data-from-phas/brief-glaxosmithkline-new-data-from-phase-iii-clinical-trial-with-fluarix-tetra-idUSFWN1QO0AS", "country": "US", "domain_rank": 408, "title": "BRIEF-Glaxosmithkline New Data From Phase III Clinical Trial With Fluarix Tetra", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-03-06T13:01:00.000+02:00", "replies_count": 0, "uuid": "fbd6a93f08379bc945fff61f8635c7458bc3a265"}, "author": "", "url": "https://www.reuters.com/article/brief-glaxosmithkline-new-data-from-phas/brief-glaxosmithkline-new-data-from-phase-iii-clinical-trial-with-fluarix-tetra-idUSFWN1QO0AS", "ord_in_thread": 0, "title": "BRIEF-Glaxosmithkline New Data From Phase III Clinical Trial With Fluarix Tetra", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "glaxosmithkline plc", "sentiment": "none"}, {"name": "fluarix tetra reuters", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "March 6, 2018 / 11:03 AM / in 26 minutes BRIEF-Glaxosmithkline New Data From Phase III Clinical Trial With Fluarix Tetra Reuters Staff 1 Min Read March 6 (Reuters) - Glaxosmithkline Plc: * ANNOUNCED NEW DATA FROM PHASE III CLINICAL TRIAL WITH FLUARIX TETRA WHICH PREVENTED INFLUENZA A AND B IN CHILDREN 6 TO 35 MONTHS OF AGE‍​ * STUDY MET ITS TWO PRIMARY ENDPOINTS * ‍STUDY ALSO FOUND THAT IIV4 REDUCED IMPACT OF INFLUENZA ON HEALTHCARE UTILISATION AND DAILY ACTIVITIES​ * FLURIX TETRA EFFICACY AGAINST MODERATE-TO-SEVERE INFLUENZA WAS 77.6% Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)", "external_links": [], "published": "2018-03-06T13:01:00.000+02:00", "crawled": "2018-03-06T13:37:35.008+02:00", "highlightTitle": ""}